ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.680,20
-0,25%
S&P 500
5.307,01
-0,27%
Dow Jones
39.671,04
-0,51%
Euro vs US Dollar
1,08241
-0,28%
Bitcoin
69.086,71
-1,49%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Theseus Pharmaceuticals Inc (THRX)

  7. Theseus Pharmaceuticals Inc (THRX) News

THRX

Theseus Pharmaceuticals (THRX)

Theseus Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:THRX
DatumZeitQuelleÜberschriftSymbolFirma
26/02/202415h00Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:THRXTheseus Pharmaceuticals Inc
16/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:THRXTheseus Pharmaceuticals Inc
14/02/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:THRXTheseus Pharmaceuticals Inc
14/02/202420h26Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:THRXTheseus Pharmaceuticals Inc
14/02/202420h24Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:THRXTheseus Pharmaceuticals Inc
14/02/202420h22Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:THRXTheseus Pharmaceuticals Inc
14/02/202416h44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
14/02/202416h35Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
14/02/202414h30PR Newswire (US)Theseus Pharmaceuticals Announces Closing of Tender OfferNASDAQ:THRXTheseus Pharmaceuticals Inc
13/02/202418h36Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
07/02/202423h21Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
07/02/202423h15Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
30/01/202414h52Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
30/01/202414h23Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
30/01/202414h00Business WireConcentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus PharmaceuticalsNASDAQ:THRXTheseus Pharmaceuticals Inc
10/01/202415h47Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:THRXTheseus Pharmaceuticals Inc
10/01/202414h51Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:THRXTheseus Pharmaceuticals Inc
22/12/202312h52Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:THRXTheseus Pharmaceuticals Inc
22/12/202312h36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
22/12/202312h30PR Newswire (US)Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value RightNASDAQ:THRXTheseus Pharmaceuticals Inc
04/12/202312h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
27/11/202312h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
27/11/202312h30PR Newswire (US)Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLCNASDAQ:THRXTheseus Pharmaceuticals Inc
24/11/202322h23Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
17/11/202322h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:THRXTheseus Pharmaceuticals Inc
15/11/202313h00Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:THRXTheseus Pharmaceuticals Inc
13/11/202322h05PR Newswire (US)Theseus Pharmaceuticals Announces Process to Explore Strategic AlternativesNASDAQ:THRXTheseus Pharmaceuticals Inc
07/11/202322h05PR Newswire (US)Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare ConferenceNASDAQ:THRXTheseus Pharmaceuticals Inc
07/11/202322h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:THRXTheseus Pharmaceuticals Inc
31/10/202321h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:THRX

Kürzlich von Ihnen besucht

LSE
43PX
Hsbc Bk. 24
BIT
WAT
Amundi Msci Water Esg Sc...
NYSE
CIC
Capitol Investment Corp IV
EU
V122S
V122S
NASDAQ
ADZA
Adeza
TSX
PRN
Profound Medical
EU
U13C
Multi Units Luxembourg
USOTC
OGGCS
Otis Collection (GM)
LSE
87WZ
Holmes 54
TSXV
ARU.WT
Aurania Resources
BOV
I1SR34
Intuitive Surgical
LSE
HEMO
Hemogenyx Pharmaceuticals
BIT
UB27SG
UniCredit Bank
LSE
61NO
Assa 24
USOTC
SSVC
SecureD Services (CE)
NASDAQ
KDNY
Chinook Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten